Latest Conference Coverage

Anton P. Porsteinsson, MD: Addressing Trial Design and Symptom Intervention in Alzheimer Disease

The director of the University of Rochester Alzheimer's Disease Care, Research and Education Program spoke about the need to rethink trial design and Alzheimer neuropsychiatric symptom management.

BAN2401 Slows Cognitive Decline in Alzheimer Disease

BAN2401 produced a dose-dependent substantial reduction in brain amyloid plaque at the highest dose, resulting in subjects converting to amyloid negative.

Lynn Kramer, MD: BAN2401 Phase IIb Clinical Study Results

This is the first large late-stage clinical trial to further support the amyloid hypothesis.

Jeff D. Williamson, MD, MHS: SPRINT-MIND Trial Preliminary Results

The SPRINT MIND trial found a statistically significant lower rate of new cases of mild cognitive impairment in the intensive treatment group.

Krista Lanctot, PhD: Nabilone Significantly Improves Agitation in Alzheimer Disease

The psychiatry and pharmacology professor spoke about the results from the first clinical trial that showed that a cannabinoid can decrease agitation in Alzheimer disease.

Clive Ballard, MD: Pimavanserin In Patients With Dementia-Related Psychosis

Efficacy was demonstrated in this patient population at the primary endpoint of 6 weeks, especially in those with more severe baseline NPI-NH-PS.

Alzheimer's Association Develops First Practice Guidelines for Clinical Evaluation of Alzheimer Disease, Other Dementias

The recommendations will provide an important tool to help improve the quality of the diagnostic process, so patients receive an early and accurate diagnosis.

Andrew Satlin, MD: Lumateperone for Agitation in Patients with Dementia, Alzheimer Disease

Data from an interim analysis of the lumateperone large phase III clinical trial for agitation in subjects with dementia is expected by the end of 2018.

James Hendrix, PhD: First Practice Guidelines for Clinical Evaluation of Alzheimer Disease Released

These guidelines will provide primary clinicians and the specialist community an important new tool to more accurately diagnose patients.

Galcanezumab Shows Efficacy in Cluster Headache, Migraine

Phase III results have shown galcanezumab is efficacious for multiple headache conditions.

Eptinezumab Reduces Monthly Migraine Days Post-Third, Fourth Infusions

The anti-CGRP treatment continues reducing migraine days a year after patients received infusions.

Rimegepant Eases Pain, Resolves Symptoms for Acute Migraine

Rimegepant significantly reduced pain and the most bothersome symptom while showing an "excellent" safety profile for patients with acute migraine attacks.

Quarterly Infusions of Eptinezumab Highly Effective for Migraine Prevention in PROMISE 2

The intravenous quarterly CGRP inhibitor eptinezumab significantly reduced monthly migraine days compared with placebo for patients with chronic migraine.

Hideki Garren, MD, PhD: Past and Future Ocrelizumab Analyses

The group medical director of neuroscience at Genentech discussed the history of a well-known therapy for multiple sclerosis: ocrelizumab (Ocrevus).

Vagus Nerve Stimulation Improves Headache, Migraine Pain

A non-invasive vagus nerve stimulation therapy significantly improved pain-free rates compared with a sham device for patients with episodic cluster headache and migraines.

Teriflunomide Improves Patient Satisfaction in Teri-PRO, TENERE Trials

The disease-modifying therapy showed significant improvements in 4 TSQM measures for patients with relapsing multiple sclerosis.

Lilyana Amezcua, MD: Better Understanding MS in the Hispanic Community

The associate professor of clinical neurology spoke about the need to understand modifiable social and cultural factors that could impact disease severity and progression.

Gregory Day, MD, MSc: The Challenge of Alzheimer Diagnosis

The clinical director of the Anti-NMDA Receptor Encephalitis Foundation spoke about the insidiousness of AD and the need for diagnosis earlier in disease progression.

NP001 Fails to Meet Primary, Secondary Endpoints in ALS Trial

The announcement was discouraging to many, as only 2 agents for ALS have been granted FDA approval in as many decades.

Alberto Espay, MD, MSc: Modifying Thought About Parkinson Disease

The UC Health professor of neurology argued that with the current view on Parkinson disease, the field is missing the mark for disease-modifying interventions.

Ralph Kern, MD, MHSc: The State of Therapies for ALS

The chief medical officer and chief operating officer of Brainstorm Cell Therapeutics spoke about a host of topics related to the treatment of amyotrophic lateral sclerosis.

Eptinezumab Migraine Prevention Sustained in 12-Month Analysis

More than two-thirds of patients treated with intravenous infusions of the CGRP inhibitor eptinezumab had an average 50% reduction in migraines.

IncobotulinumtoxinA Successful in Treating Sialorrhea in Parkinson, Other Neurological Conditions

Study findings revealed statistically significant results at week 4 for the 100-U dose compared to placebo. The 75-U dose, while effective, did not achieve statistical significance.

Siponimod Reduces Disability Progression in Secondary Progressive Multiple Sclerosis

The data from the phase III EXPAND study indicated to the researchers that this risk reduction obtained with siponimod was substantially isolated from MS relapse.

Erenumab Displays Success in Patients Who Failed 2 or More Preventative Migraine Treatments

The calcitonin gene-related peptide inhibitor lowered monthly migraine days by ≥50% in 30.3% of patients compared to 13.7% on placebo.